EDX Medical publishes Annual Report and Notice of AGM

EDX Medical Group plc

EDX Medical Group Plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced that its annual general meeting (AGM) will be held at Mezzanine Room, 1 Wimpole Street, Westminster, London, W1G 0AE on 30 September 2024 at 2:00 p.m.

The annual report and financial statements for the year ended 31 March 2024, Notice of AGM and Form of Proxy will be posted today, 4 September 2024, to eligible shareholders.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

EDX Medical Group raises £3.0 million to accelerate its prostate cancer ‘super test’

EDX Medical Group plc has secured £3 million by issuing 21.4 million new shares at 14p each, boosting its innovative prostate cancer diagnostic efforts.

EDX Medical Group signs master service agreement with The Royal Marsden

EDX Medical Group has secured a three-year master service agreement with The Royal Marsden NHS Foundation Trust to provide innovative diagnostic solutions for cancer care.

EDX Medical’s Prof. Chris Evans on Prostate Cancer Breakthrough & Future Plans (AQSE:EDX)

Discover how EDX Medical Group’s innovative super-test for prostate cancer aims to transform early detection and precision diagnostics in the fight against cancer.

EDX Medical develops new ‘super test’ for prostate cancer

EDX Medical Group plc unveils a revolutionary AI-driven prostate cancer 'super test,' offering high accuracy and personalised treatment insights.

Exploring EDX Medical: An Interview with CEO Mike Hudson

Explore how EDX Medical Group plc, led by CEO Mike Hudson, is transforming healthcare through innovative diagnostics, personalized medicine, and strategic partnerships.

Search

Search